Neuroblastoma Recurrent Clinical Trial
Official title:
A Phase I/II Trial of DFMO in Combination With Bortezomib in Patients With Relapsed or Refractory Neuroblastoma
The purpose of this research study is to evaluate an investigational drug (DFMO) in combination with bortezomib, for relapsed and refractory neuroblastoma. DFMO is an investigational drug because it has not been approved by the U.S. Food and Drug Administration (FDA). This study will look at the safety and tolerability of DFMO in combination with bortezomib as well as the tumors response to this study drug.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03242603 -
Immunotherapy of Neuroblastoma Patients Using a Combination of Anti-GD2 and NK Cells
|
Phase 1/Phase 2 | |
| Terminated |
NCT04560166 -
Naxitamab and GM-CSF in Combination With IT in Patients With High-Risk Neuroblastoma
|
Phase 2 | |
| Recruiting |
NCT04903899 -
177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma
|
Phase 2 | |
| Active, not recruiting |
NCT04239092 -
9-ING-41 in Pediatric Patients With Refractory Malignancies.
|
Phase 1 | |
| Recruiting |
NCT03373097 -
Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05754684 -
Quadruple Immunotherapy for Neuroblastoma
|
Phase 2 | |
| Completed |
NCT01467986 -
Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma
|
Phase 2 | |
| Completed |
NCT02258815 -
CH14.18 1021 Antibody and IL2 After Haplo SCT in Children With Relapsed Neuroblastoma
|
Phase 2 |